459 related articles for article (PubMed ID: 15690321)
1. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients.
Musso C; Cochran E; Javor E; Young J; Depaoli AM; Gorden P
Metabolism; 2005 Feb; 54(2):255-63. PubMed ID: 15690321
[TBL] [Abstract][Full Text] [Related]
2. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.
Javor ED; Ghany MG; Cochran EK; Oral EA; DePaoli AM; Premkumar A; Kleiner DE; Gorden P
Hepatology; 2005 Apr; 41(4):753-60. PubMed ID: 15791619
[TBL] [Abstract][Full Text] [Related]
3. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy.
Oral EA; Ruiz E; Andewelt A; Sebring N; Wagner AJ; Depaoli AM; Gorden P
J Clin Endocrinol Metab; 2002 Jul; 87(7):3110-7. PubMed ID: 12107209
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human leptin in women with hypothalamic amenorrhea.
Welt CK; Chan JL; Bullen J; Murphy R; Smith P; DePaoli AM; Karalis A; Mantzoros CS
N Engl J Med; 2004 Sep; 351(10):987-97. PubMed ID: 15342807
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of allogeneic bone marrow transplantation (BMT) on pituitary, gonad, thyroid and adrenal function in adults.
Kauppila M; Koskinen P; Irjala K; Remes K; Viikari J
Bone Marrow Transplant; 1998 Aug; 22(4):331-7. PubMed ID: 9722067
[TBL] [Abstract][Full Text] [Related]
6. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
7. [Hyperinsulinemia, insulin-like growth factor-I, insulin-like growth factor-binding protein-1, and sex-hormone binding-globulin in prepubertal and pubertal girls with premature adrenarche].
Ságodi L; Barkai L; Tombácz A; Vámosi I
Orv Hetil; 2003 Jan; 144(2):67-72. PubMed ID: 12632745
[TBL] [Abstract][Full Text] [Related]
8. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism.
Apter D; Bützow T; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1995 Oct; 80(10):2966-73. PubMed ID: 7559882
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome.
Cataldo NA; Abbasi F; McLaughlin TL; Basina M; Fechner PY; Giudice LC; Reaven GM
Hum Reprod; 2006 Jan; 21(1):109-20. PubMed ID: 16155076
[TBL] [Abstract][Full Text] [Related]
10. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
[TBL] [Abstract][Full Text] [Related]
11. [The effects of hyperinsulinmia and insulin-like growth factor-1 on hyperandrogenism in polycystic ovarian syndrome].
Liang X; Zhuang G; Fan Q
Zhonghua Yi Xue Za Zhi; 1997 Apr; 77(4):266-9. PubMed ID: 9596926
[TBL] [Abstract][Full Text] [Related]
12. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.
Lee JH; Chan JL; Sourlas E; Raptopoulos V; Mantzoros CS
J Clin Endocrinol Metab; 2006 Jul; 91(7):2605-11. PubMed ID: 16636130
[TBL] [Abstract][Full Text] [Related]
13. [Relationship between leptin and insulin sensitivity in patients with polycystic ovary syndrome].
Maliqueo M; Pérez-Bravo F; Calvillán M; Piwonka V; Castillo T; Sir-Petermann T
Med Clin (Barc); 1999 Oct; 113(14):526-30. PubMed ID: 10605667
[TBL] [Abstract][Full Text] [Related]
14. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
15. Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy.
El-Khayat HA; Abd El-Basset FZ; Tomoum HY; Tohamy SM; Zaky AA; Mohamed MS; Hakky SM; El Barbary NS; Nassef NM
Epilepsia; 2004 Sep; 45(9):1106-15. PubMed ID: 15329076
[TBL] [Abstract][Full Text] [Related]
16. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
17. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
[TBL] [Abstract][Full Text] [Related]
18. Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome.
Garmes HM; Tambascia MA; Zantut-Wittmann DE
Gynecol Endocrinol; 2005 Dec; 21(6):317-23. PubMed ID: 16390779
[TBL] [Abstract][Full Text] [Related]
19. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
[TBL] [Abstract][Full Text] [Related]
20. Effects of chronic hyperandrogenism and/or administered central nervous system insulin on ovarian manifestation and gonadotropin and steroid secretion.
Allon MA; Leach RE; Dunbar J; Diamond MP
Fertil Steril; 2005 Apr; 83 Suppl 1():1319-26. PubMed ID: 15831308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
